Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06570330 · ClinicalTrials.gov registry record · NA

Adult HMO Supplementation and the Gut Microbiome

A NA study, sponsored by Seeding.

Completed
Registry status
NA
Development phase
32
Enrollment target

NCT06570330: Completed NA study, sponsored by Seeding.

NCT06570330 is a NA study that has completed, run by Seeding. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06570330, a NA study, has completed, sponsored by Seeding.

COMPLETED
Registry status
NA
Development phase
32 participants
Enrollment target

Study Summary

The goal of this study is to assess the impact of Layer Origin's SuperHMO prebiotic formulation on the healthy adult gut microbiome. Over the course of 30 days, intervention participants will take SuperHMO prebiotic formulation daily. Control participants will take a placebo daily. We will measure all participants\' gut microbiome using a gut health test before taking SuperHMO prebiotic or placebo and after 30 days of taking the supplement. We hypothesize that taking the SuperHMO prebiotic will improve gut health measurements such as the potential to produce short-chain fatty acids.

Primary Outcome

The investigators will specifically measure the difference in Bifidobacterium spp., Akkermansia spp., Eubacterium rectale-Clostridium Coccoides group, and Faecalibacterium prausnitzii, at baseline and at 30 days.

Interventions

  • DIETARY_SUPPLEMENT SuperHMO
  • DIETARY_SUPPLEMENT Non-GMO corn Maltodextrin, Rapid Absorption

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2024-08-22
Est. Completion 2025-07-30
Phase NA
Seeding

3 total trials

What the finished NCT06570330 record still lists

NCT06570330 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which SuperHMO is the first listed.

NCT06570330 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06570330 about?

NCT06570330 is a clinical study titled "Adult HMO Supplementation and the Gut Microbiome". The goal of this study is to assess the impact of Layer Origin's SuperHMO prebiotic formulation on the healthy adult gut microbiome. Over the course of 30 days, intervention participants will take SuperHMO prebiotic formulation daily. Control participants will take a placebo daily. We will measure a...

What is the current status of trial NCT06570330?

This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2024-08-22. Estimated completion is 2025-07-30.

What interventions are being tested in trial NCT06570330?

The interventions under investigation include: SuperHMO (DIETARY_SUPPLEMENT), Non-GMO corn Maltodextrin, Rapid Absorption (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06570330?

This trial is sponsored by Seeding, which has 3 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06570330's enrollment target sits among peer trials

32 1578th of 2000 higher than 409 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06570330, the US trial registry maintained by the National Library of Medicine. NCT06570330 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.